See more : ASML Holding N.V. (ASML.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Valiant Laboratories Limited (VALIANTLAB.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valiant Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Polski Koncern Naftowy ORLEN Spólka Akcyjna (PSKOF) Income Statement Analysis – Financial Results
- McCoy Global Inc. (MCB.TO) Income Statement Analysis – Financial Results
- Tech and Energy Transition Corporation (TETCU) Income Statement Analysis – Financial Results
- East Tender Optoelectronics Corporation (6588.TWO) Income Statement Analysis – Financial Results
- USA Recycling Industries, Inc. (USRI) Income Statement Analysis – Financial Results
Valiant Laboratories Limited (VALIANTLAB.BO)
About Valiant Laboratories Limited
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 1.82B | 3.34B | 2.92B | 1.82B |
Cost of Revenue | 1.88B | 2.85B | 2.39B | 1.24B |
Gross Profit | -60.66M | 491.80M | 523.21M | 583.90M |
Gross Profit Ratio | -3.33% | 14.73% | 17.95% | 32.02% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 6.53M | 4.77M | 5.55M |
Selling & Marketing | 0.00 | 17.93M | 12.68M | 6.29M |
SG&A | -101.74M | 24.46M | 17.45M | 11.84M |
Other Expenses | 138.03M | 2.65M | 4.62M | 330.00K |
Operating Expenses | 36.29M | 153.52M | 123.16M | 109.95M |
Cost & Expenses | 1.92B | 3.00B | 2.52B | 1.35B |
Interest Income | 1.76M | 970.00K | 5.45M | 3.70M |
Interest Expense | 2.54M | 2.53M | 730.00K | 17.84M |
Depreciation & Amortization | 19.66M | 15.63M | 24.90M | 26.07M |
EBITDA | 12.74M | 399.53M | 442.67M | 514.14M |
EBITDA Ratio | 0.70% | 10.88% | 15.22% | 28.19% |
Operating Income | 0.00 | 341.57M | 418.74M | 488.07M |
Operating Income Ratio | 0.00% | 10.23% | 14.36% | 26.76% |
Total Other Income/Expenses | -7.70M | 39.80M | -1.70M | -17.84M |
Income Before Tax | -7.70M | 381.36M | 417.04M | 470.23M |
Income Before Tax Ratio | -0.42% | 11.42% | 14.31% | 25.78% |
Income Tax Expense | -10.89M | 91.38M | 142.08M | 164.30M |
Net Income | 3.20M | 289.98M | 274.96M | 305.93M |
Net Income Ratio | 0.18% | 8.68% | 9.43% | 16.78% |
EPS | 0.08 | 8.91 | 6.23 | 6.93 |
EPS Diluted | 0.08 | 8.91 | 6.23 | 6.93 |
Weighted Avg Shares Out | 38.01M | 32.56M | 44.12M | 44.12M |
Weighted Avg Shares Out (Dil) | 38.01M | 32.56M | 44.12M | 44.12M |
Source: https://incomestatements.info
Category: Stock Reports